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Available online 26 November 2015The KCL032 human embryonic stem cell linewas derived from a normal healthy blastocyst donated for research.
The ICM was isolated using laser microsurgery and plated on γ-irradiated human foreskin ﬁbroblasts. Both the
derivation and cell line propagation were performed in an animal product-free environment and under current
Good Manufacturing Practice (cGMP) standards. Pluripotent state and differentiation potential were conﬁrmed
by in vitro assays.
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ex Female 46, XX
rade Clinical
isease status Healthy/unaffected
aryotype (aCGH) Gain in region 5p14.3
NP array Gain in region 5p14.3 (Canham et al., 2015)NA ﬁngerprint
Allele sizes (in bp) of 16 microsatellite markers
speciﬁc for chromosomes 13, 18 and 21 (Jacquet et al.,
2013)LA typing
HLA-A2,11; B51,62; Bw4,6; Cw4,9; DR4,13; DR52,53;
DQ6,7 (Jacquet et al., 2013)iability testing Pass
ycoplasma Negative
erility Pass
luripotent markers
(immunostaining)
(Fig. 1)NANOG, OCT4, TRA-1-60, TRA-1-81, AP activityhree germ layers
differentiation in vitro
(immunostaining)
(Fig. 2)Endoderm: AFP
Ectoderm: TUBB3 (tubulin, beta 3 class III)
Mesoderm: ACTA2 (actin, alpha 2, smooth muscle)bling lines available KCL033, KCL034SiWe generated KCL032 clinical grade hESC line following protocols,
established previously (Ilic et al., 2012; Stephenson et al., 2012), and
now adapted to cGMP conditions. The expression of the pluripotency
markers was tested after freeze/thaw cycle (Fig. 1). Differentiation po-
tential into three germ layers was veriﬁed in vitro (Fig. 2).
Molecular karyotyping identiﬁed a novel 2.4 Mb gain on chromo-
some 5p14.3, containing a single gene, CDH18 (Cadherin-18), that was
also present in one of two sibling cell lines, KCL033, but not in KCL034,
a third sibling. A duplication of this size has not been reported to date,
but its presence in two sibling hESC lines strongly suggests that it was
inherited from one of the parents rather than by acquisition during
hESC derivation and culture (Canham et al., 2015). The 2498.8 bp gain
starts at bp 19,086,546 and ends at bp 21,585,311 as referred to
Human Genome Build 38.
We also generated research grade of KCL032 line that is adapted to
feeder-free conditions.3. Materials and methods
3.1. Consenting process
We distribute Patient Information Sheet (PIS) and consent form to
the in vitro fertilization (IVF) patients if they opted to donate to researchncy markers. Pluripotency is conﬁrmed by immunostaining (Oct
ine-phalloidin (red), are present in both feeders and hES cell coembryos that were stored for 5 or 10 years. They mail signed consent
back to us and that might be months after the PIS and consent were
mailed to them. For in the meantime new versions of PIS/consent are
implemented, we do not send these to the patients or ask them to re-
sign; the whole process is done with the version that was given them
initially. The PIS/consent documents (FRO-V.6) were created on Dec.
18, 2008. HFEA Code of Practice that was in effect at the time of docu-
ment creation: Edition 7 — R.4 (http://www.hfea.gov.uk/2999.html).
The donor couple signed the consent on May 26, 2009. HFEA Code of
Practice that was in effect at the time of donor signature: Edition 7 —
R.4. HFEA Code of Practice Edition 7 — R.4 was in effect: 02 Oct. 2008–
30 Sep. 2009.
3.2. Embryo culture and micromanipulation
Embryo culture and laser-assisted dissection of inner cell mass
(ICM) were carried out as previously described in details (Ilic et al.,
2012; Stephenson et al., 2012). The cellular area containing the ICM
was then washed and transferred to plates containing mitotically
inactivated human neonatal foreskin ﬁbroblasts (HFF).
3.3. Cell culture
ICMplated onmitotically inactivatedHFFwere cultured as described
(Ilic et al., 2012; Stephenson et al., 2012). TE cells were removed me-
chanically fromoutgrowth (Ilic et al., 2007; Ilic et al., 2010). hES colonies
were expanded and cryopreserved at the third passage.
3.4. Viability test
Straws with the earliest frozen passage (p.2–3) are thawed and new
colonies are counted three days later. These colonies are then expanded
up to passage 8, atwhich point cellswere part frozen and part subjected
to standard battery of tests (pluripotency markers, in vitro and in vivo
differentiation capability, genetics, sterility, mycoplasma).
3.5. Pluripotency markers
Pluripotencywas assessed using two different techniques: enzymat-
ic activity assay [alkaline phosphatase (AP) assay] and immunostaining
as described (Ilic et al., 2012; Stephenson et al., 2012).4, Nanog, TRA-1-60, TRA-1-81) and alkaline phosphatase (AP) activity assay. Actin stress
lonies, whereas AP activity (green) is detected only in hES cells. Scale bar, 50 μm.
Fig. 2.Differentiation of three germ layers in vitro is conﬁrmed by detection of markers: smoothmuscle actin (red) formesoderm, β-III tubulin (red) for ectoderm andα-fetoprotein (red)
for endoderm. Nuclei are visualized with Hoechst 33342 (blue). Scale bar, 50 μm.
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DNA was extracted from hES cell cultures using a Chemagen DNA
extraction robot according to the manufacturer's instructions. Ampliﬁ-
cation of polymorphic microsatellite markers was carried out as de-
scribed (Ilic et al., 2012). Allele sizes were recorded to give a unique
ﬁngerprint of each cell line.
3.7. Array comparative genomic hybridization (aCGH)
aCGH was performed as described in details (Ilic et al., 2012).
3.8. SNP array
SNP array was performed as described in details (Canham et al.,
2015).
3.9. HLA typing
HLA-A, -B and -DRB1 typing was performed with a PCR sequence-
speciﬁc oligonucleotide probe (SSOP; Luminex, Austin, TX, USA) hybrid-
ization protocol at the certiﬁed Clinical Transplantation Laboratory,
Guy's and St. Thomas' NHS Foundation Trust and Serco Plc. (GSTS) Pa-
thology (Guy's Hospital, London, UK) as described (Jacquet et al., 2013).
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